By Fineline Cube 
Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has secured two additional indication approvals from the European Commission (EC) for its anti-PD-1 monoclonal antibody HanSiZhuang (serplulimab, HLX10), significantly broadening its commercial scope in Europe’s $45 billion immuno-oncology market.
Newly Approved European Indications
| Indication | Patient Population | Combination Regimen | Biomarker Requirement |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma (ESCC) | Unresectable locally advanced, recurrent, or metastatic | Fluoropyrimidine + platinum-based chemotherapy | PD-L1 CPS ≥ 5 |
| Non-Squamous NSCLC (nsNSCLC) | Unresectable locally advanced or metastatic | Carboplatin + pemetrexed | EGFR wild-type, ALK/ROS1 negative |
These approvals complement HanSiZhuang’s existing European authorization for first-line extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide, granted previously.
Global Regulatory Portfolio & Commercial Strategy
Comprehensive Approval Landscape
- China: MSI-H solid tumors, sqNSCLC, ES-SCLC, ESCC, nsNSCLC
- European Union: ES-SCLC, ESCC, nsNSCLC (3 indications)
- Additional Markets: UK, Indonesia, Cambodia, Thailand, Malaysia, Singapore, India
- Orphan Drug Designations: United States, Switzerland, South Korea
Strategic Partnership Framework
The October 2023 licensing agreement with Intas Pharmaceuticals Ltd. grants the Indian firm exclusive commercialization rights in Europe and India, enabling Henlius to leverage Intas’ established European oncology distribution infrastructure while maintaining manufacturing control and receiving tiered royalties.
Clinical Differentiation & Market Position
Therapeutic Advantages
HanSiZhuang represents Henlius’ first innovative monoclonal antibody and demonstrates:
- Broad tumor agnostic activity in MSI-H solid tumors
- Superior progression-free survival in head-to-head trials against reference PD-1 inhibitors
- Favorable safety profile with reduced immune-related adverse events compared to competitors
- Cost-effectiveness positioning in price-sensitive European markets
Competitive Landscape Analysis
With these new approvals, HanSiZhuang becomes one of only four PD-1 inhibitors with European marketing authorization for both ESCC and nsNSCLC, competing directly with established players including Merck’s Keytruda, Bristol Myers Squibb’s Opdivo, and Roche’s Tecentriq.
Revenue Outlook & Strategic Impact
- European Market Potential: Combined ESCC and nsNSCLC addressable market estimated at €800 million annually
- Royalty Structure: Intas partnership provides upfront payments plus 15-25% royalty rates on net sales
- Manufacturing Leverage: Existing GMP facilities in Shanghai support global supply requirements
- Pipeline Synergies: HanSiZhuang serves as backbone for combination trials with Henlius’ other oncology assets
The expanded European indications validate Henlius’ international regulatory strategy and position the company as a leading Chinese biotech with genuine global commercial capabilities in the competitive immuno-oncology space.
Forward-Looking Statements
This brief contains forward-looking statements regarding commercial performance, market adoption, and revenue projections for HanSiZhuang in Europe. Actual results may differ due to competitive dynamics, pricing negotiations, and evolving treatment guidelines.-Fineline Info & Tech